Can-Fite BioPharma Ltd. (CANF)
NYSEAMERICAN: CANF · Real-Time Price · USD
2.960
+0.040 (1.37%)
Apr 22, 2026, 4:00 PM EDT - Market closed
Can-Fite BioPharma Employees
Can-Fite BioPharma had 5 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
5
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$81,000
Profits / Employee
-$1,965,600
Market Cap
6.64M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 5 | 0 | - |
| Dec 31, 2024 | 5 | -3 | -37.50% |
| Dec 31, 2023 | 8 | 0 | - |
| Dec 31, 2022 | 8 | 0 | - |
| Dec 31, 2021 | 8 | 0 | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| PMGC Holdings | 34 |
| FibroBiologics | 15 |
| XTL Biopharmaceuticals | 10 |
| Purple Biotech | 10 |
| Akari Therapeutics, | 6 |
| Enveric Biosciences | 6 |
| Addex Therapeutics | 2 |
| Xenetic Biosciences | 2 |
CANF News
- 23 days ago - Can-Fite BioPharma (CANF) Advances Osteoarthritis Treatment for Dogs - GuruFocus
- 23 days ago - Can-Fite's Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026 - GlobeNewsWire
- 27 days ago - Can-Fite Reports 2025 Financial Results and Ongoing Clinical Progress Highlighting Positive Data in Phase 2a Pancreatic cancer and 9 Years Cancer-Free Survival in Liver Cancer Patient - GlobeNewsWire
- 5 weeks ago - Can-Fite BioPharma (CANF) Secures Key Patent for Obesity Treatment - GuruFocus
- 5 weeks ago - Can-Fite Expands Namodenoson anti-Obesity Franchise with Israeli Patent Allowance - GlobeNewsWire
- 7 weeks ago - Can-Fite's Namodenoson Hits Phase 2a Goal; Raises $4M Via Warrants - Nasdaq
- 7 weeks ago - Micro-Cap Can-Fite BioPharma Shares Surge On Successful Pancreatic Cancer Drug Study - Benzinga
- 7 weeks ago - Can-Fite BioPharma (CANF) Achieves Positive Results in Pancreatic Cancer Study - GuruFocus